STAT3 and neoplasm: In animal studies, treatment with STAT3 inhibitors (such as WP1066) has been shown to significantly reduce the accumulation of MDSCs in murine tumor models, while restoring T cell proliferation and cytotoxic activity (65), supporting the potential of this pathway as a therapeutic target.